Document Detail

Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
MedLine Citation:
PMID:  22025028     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Pemphigus is the most common and severe autoimmune bullous disease in Korea.
OBJECTIVE: The aim of this clinical study was to evaluate the clinical features, treatment modalities and long-term prognosis of pemphigus in Korea.
METHODS: We conducted a retrospective analysis of 199 patients diagnosed with pemphigus vulgaris (PV) and pemphigus foliaceus (PF) between 1993 and 2008. Complete and partial remissions were evaluated according to the definitions proposed by the International Pemphigus Committee.
RESULTS: The mean age of onset was 46.1 years, and the female-to-male ratio was 1.1:1.0 (women: 102, men: 97). The ratio of PV to PF was 1.1:1.0 (PV: 104, PF: 95). Complete/partial remission rate for PV was 77% at 5 years and 94% at 10 years after initial diagnosis. The corresponding rate for PF was 87% at 5 years and 98% at 10 years after initial diagnosis. There was no difference in time to remission between mild cases (treated with prednisolone, Pd, alone) and severe cases (treated with Pd ± adjuvant therapy). Sixteen patients, who were recalcitrant to conventional therapy, received rituximab; all of these achieved overall remission without adverse effects. Eight (8%) PV patients and 5 (5%) PF patients died during the 16-year follow-up period.
CONCLUSIONS: Most patients reached remission within 10 years of treatment. Pd + adjuvant therapy did not yield a better prognosis than Pd alone. All patients who received rituximab experienced remarkable clinical improvement. Rituximab is an effective and safe drug for patients who are resistant to conventional therapy.
Mi Ri Kim; Hyeon Chang Kim; Soo-Chan Kim
Related Documents :
22075678 - Pharmacologic management during therapeutic hypothermia.
21826738 - Qtc prolongation: is clozapine safe? study of 82 cases before and after clozapine treat...
25470478 - Successful treatment of chronic nausea and vomiting related to body piercing and tattoo...
9438318 - Highly effective second-line anti-helicobacter pylori therapy in patients with previous...
23531208 - Blood transfusion in cardiac surgery is a risk factor for increased hospital length of ...
17308738 - Malawi's contribution to "3 by 5": achievements and challenges.
Publication Detail:
Type:  Journal Article     Date:  2011-10-21
Journal Detail:
Title:  Dermatology (Basel, Switzerland)     Volume:  223     ISSN:  1421-9832     ISO Abbreviation:  Dermatology (Basel)     Publication Date:  2011  
Date Detail:
Created Date:  2011-11-29     Completed Date:  2012-04-18     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  9203244     Medline TA:  Dermatology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  182-8     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 S. Karger AG, Basel.
Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Infective Agents / therapeutic use*
Anti-Inflammatory Agents / therapeutic use*
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Azathioprine / therapeutic use
Cyclophosphamide / therapeutic use
Cyclosporine / therapeutic use
Dapsone / therapeutic use
Drug Therapy, Combination
Immunoglobulins, Intravenous / therapeutic use
Immunologic Factors / therapeutic use*
Immunosuppressive Agents / therapeutic use*
Methylprednisolone / therapeutic use
Middle Aged
Mycophenolic Acid / analogs & derivatives,  therapeutic use
Pemphigus / drug therapy*,  pathology
Prednisolone / therapeutic use*
Republic of Korea
Retrospective Studies
Severity of Illness Index
Time Factors
Treatment Outcome
Young Adult
Reg. No./Substance:
0/Anti-Infective Agents; 0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal, Murine-Derived; 0/Immunoglobulins, Intravenous; 0/Immunologic Factors; 0/Immunosuppressive Agents; 0/rituximab; 24280-93-1/Mycophenolic Acid; 446-86-6/Azathioprine; 50-18-0/Cyclophosphamide; 50-24-8/Prednisolone; 59865-13-3/Cyclosporine; 80-08-0/Dapsone; 83-43-2/Methylprednisolone; 9242ECW6R0/mycophenolate mofetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  On-chip integrated labelling, transport and detection of tumour cells.
Next Document:  The clinical importance of emerging Campylobacter species.